Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 3: Pembrolizumab Combinations in Advanced NSCLC
NCT04165096Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
Phase 2, open-label trial of boserolimab, mk-4830 and rolistobart in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 53 months. Started Jan 2020; status: completed.
02
Drugs
boserolimabmk-4830rolistobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04165096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165096.